Desvenlafaxine data show significant improvement in symptoms of depression in adults v...( Madison N.J. May 25 2006 Wyeth Phar...),Health

Madison, N.J., May 25, 2006 Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), this week presented for the first time phase 3 data and results from other studies concerning its investigational drug for major depressive disorder (MDD), desvenlafaxine succinate (DVS-233), a novel serotonin-norepinephrine reuptake inhibitor (SNRI) at the 2006 American Psychiatric Association Annual Meeting in Toronto.

Overall, the phase 3 data results showed desvenlafaxine succinate significantly improved depressive symptoms in adult patients compared to placebo. In a separate study investigating QTc prolongation involving healthy adult female subjects, desvenlafaxine succinate 200 mg and 600 mg doses did not affect the QT interval at the study's primary endpoint at eight hours post dose. Studying a drug's effect on the QT interval is one of many methods used to help determine a drug's overall safety profile.

Wyeth Research discovered and developed desvenlafaxine succinate. In December 2005, Wyeth submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for desvenlafaxine succinate for the treatment of MDD.

"The phase 3 data showed that desvenlafaxine succinate can help improve symptoms in adult patients suffering with depression," says Nicholas A. DeMartinis, M.D., Assistant Professor and Associate Director of Clinical Operations of the Neuropsychopharmacology Treatment Research and Training Center at the University of Connecticut Health Center and principal investigator of the clinical trial presented in the scientific session. "Because a substantial number of patients with depression do not respond to current antidepressant treatments, it is important that new treatments continue to be developed to provide patients and physicians with additional treatment options," Dr. DeMartinis adds.

"Wyeth is pleased to be able to report these promising findings that have the potential to add value to the management and treatment of maj
'"/>


25-May-2006

Page: 1 2 3 4
Related medicine news :

1. Trial stops after stroke and mortality significantly reduced by blood
2. Africa: International volunteer impact small, but significant
3. Investigational nonstimulant Guanfacine XR significantly improved child, adolescent ADHD symptoms
4. Daytrana provides significant effectiveness in both boys and girls with ADHD
5. Long-term treatment with VYVANSE, first prodrug stimulant, demonstrates significant efficacy in ADHD
6. Full-term, low-birth-weight babies at significantly greater risk for early respiratory symptoms
7. Educational expenses for residents equals significant amount of salary
8. Once-yearly treatment significantly reduces bone fractures in women with postmenopausal osteoporosis
9. 20-year study shows significant rise in childhood obesity, especially among girls
10. New study: Pine bark significantly reduces endometriosis
11. Regular acupressure can significantly reduce agitated behavior in dementia